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Abstract
Objective To examine the effectiveness of screening for intimate partner
violence conducted within healthcare settings to determine whether or
not screening increases identification and referral to support agencies,
improves women’s wellbeing, decreases further violence, or causes
harm.
Design Systematic review and meta-analysis of trials assessing
effectiveness of screening. Study assessment, data abstraction, and
quality assessment were conducted independently by two of the authors.
Standardised estimations of the risk ratios and 95% confidence intervals
were calculated.
Data sources Nine databases searched up to July 2012 (CENTRAL,
Medline, Medline(R), Embase, DARE, CINAHL, PsycINFO, Sociological
Abstracts, and ASSIA), and five trials registers searched up to 2010.
Eligibility criteria for selecting studies Randomised or
quasi-randomised trials of screening programmes for intimate partner
violence involving all women aged ≥16 attending a healthcare setting.
We included only studies in which clinicians in the intervention arm
personally conducted the screening, or were informed of the screening
result at the time of the consultation, compared with usual care (or no
screening). Studies of screening programmes that were followed by
structured interventions such as advocacy or therapeutic intervention
were excluded.
Results 11 eligible trials (n=13 027) were identified. In six pooled studies
(n=3564), screening increased the identification of intimate partner
violence (risk ratio 2.33, 95% confidence interval 1.39 to 3.89),
particularly in antenatal settings (4.26, 1.76 to 10.31). Based on three
studies (n=1400), we detected no evidence that screening increases
referrals to domestic violence support services (2.67, 0.99 to 7.20). Only
two studies measured women’s experience of violence after screening
(three to 18 months after screening) and found no reduction in intimate
partner violence. One study reported that screening does not cause
harm.
Conclusions Though screening is likely to increase identification of
intimate partner violence in healthcare settings, rates of identification
from screening interventions were low relative to best estimates of
prevalence of such violence. It is uncertain whether screening increases
effective referral to supportive agencies. Screening does not seem to
cause harm in the short term, but harm was measured in only one study.
As the primary studies did not detect improved outcomes for women
screened for intimate partner violence, there is insufficient evidence for
screening in healthcare settings. Studies comparing screening versus
case finding, or screening in combination with therapeutic intervention
for women’s long term wellbeing, are needed to inform the
implementation of identification policies in healthcare settings.
Introduction
Intimate partner violence is a major cause of death and disability
on a worldwide scale.1 2 TheWorld Health Organization (WHO)
highlights violence against women as a priority health issue,
with one in three women globally experiencing physical and/or
sexual violence from a partner.2 3 While the rates of intimate
partner violence differ in low, middle, and high income regions,
the health effects are similar across the globe.2 In all countries,
women experiencing such violence often present in health
settings and require wide ranging medical services.4 Since the
late 1990s, many health professional associations have published
clinician guidelines on how to identify and respond to women
who have been abused,5 and health professionals are increasingly
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required to undertake screening in accordance with national
health policies.6 7 In some countries, screening is advocated
without sufficient resources or referral options in place, and
clinicians often lack skills and knowledge to respond
appropriately because of a lack of training.8 TheWHO clinician
guidelines recommend against screening, particularly in low to
middle income health settings.5 On the other hand, a recent
systematic review to update the 2004 recommendations from
the US Preventive Services Task Force supported screening but
included only a subset of trials relevant to the United States.9
Screening in healthcare settings aims to identify women with
current or past experience of violence from an intimate partner
or ex-partner so they can be referred to, or be offered, other
(therapeutic) interventions leading to beneficial outcomes. There
are, however, many barriers that influence the capacity of
women to disclose such events and that impact on the
effectiveness of screening.10 Intimate partner violence is
therefore problematic when traditional screening criteria are
applied11 because it is a complex social phenomenon rather than
a disease. Nonetheless, the decision to implement screening
programmes still requires evidence of effectiveness. It is
important to distinguish between options of universal screening
(application of a standardised question to all women without
“symptoms” according to a procedure that varies little from
place to place), selective screening (when high risk groups, such
as pregnant women or those seeking terminations of pregnancy,
are screened), routine inquiry (when all women are asked but
the method/question might vary according to the provider or
woman’s situation—for example, taking a social history in a
clinical setting), and case finding (asking if indicators of risk
are present).12 For the purposes of this review, we included
studies of universal and selective screening, with the added
proviso that the clinician be aware of the woman’s abuse status
(either through direct enquiry with the women themselves or
being notified of a positive result of screening). Studies of
interventions that went beyond inquiry and initial
support/referral were excluded given that it is not feasible for
most health professionals to deliver more intensive therapies
(because of lack of time and skill for advocacy). More
importantly, however, it was necessary to isolate the screening
effect from other follow-up interventions to provide evidence
of the independent contribution of screening.
Based on a recently published Cochrane Review,12we reviewed
the evidence for health service screening. Our review question
was whether screening women for intimate partner violence in
healthcare settings is safe, effective, and cost effective. We
hypothesised that screening can, as a first step, lead to improved
identification, information giving, and referral to support
services (primary outcomes), which in turn might lead to a
reduction in abuse and an improvement in health and wellbeing
(secondary outcomes) in the longer term.13 14
Methods
The protocol for this review can be accessed through the
Cochrane Library.15
Inclusion criteria
Types of studies—We included any studies that allocated
individual women or clusters of women by a random or a
quasi-random method (for example, alternate allocation) to a
screening intervention compared with usual care (or in a trial
with a condition when clinicians were not aware of women’s
screening results).
Participants—Studies included women (aged ≥16) attending a
healthcare setting, including general (family) practice; antenatal
and postnatal services; hospital emergency, inpatient or
outpatient services; specialists (such as obstetrics and
gynaecology, psychiatry); community health services; drug and
alcohol services; mental health services.
Interventions—Screening was defined as any of a range of
methods (face to face, written, or computerised survey, involving
specific inquiry about intimate partner violence or inquiry about
intimate partner violence as part of general psychosocial
screening) that aimed for all women patients in a healthcare
setting to be asked about their experience of such violence. This
included the use of validated screening tools as well as simply
asking one or a range of questions related to intimate partner
violence on one or several occasions. We included only studies
in which clinicians in the intervention arm personally conducted
the screening, or were informed of the screening result at the
time of the consultation, and women in the control groups
received usual care or, when screening was conducted for
research purposes (such as to establish participant eligibility),
the clinicians were not informed of (blinded to) the result of
screening and therefore could not act on the information. We
excluded studies of interventions that involved structured clinical
intervention after screening.
Search methods
We ran three searches for this review (from their start dates to
September 2009, updated in September 2011 and July 2012)
using terms for intimate partner violence, identification, and
referral appropriate to the following databases: Cochrane Central
Register of Controlled Trials, Medline, Medline(R), Embase,
DARE, CINAHL PLUS, PsycINFO, ASSIA, and Sociological
Abstracts. We searched the following trial registers to 2010:
metaRegister of Controlled Trials (mRCT),WHO International
Clinical Trials Registry Platform, ClinicalTrials.gov, Australian
NewZealand Clinical Trials Registry, and International Standard
Randomised Controlled Trial Register. We also searched the
websites of the WHO (www.who.int/topics/violence/en),
Violence Against Women Online Resources (www.vaw.umn.
edu), and Domestic Violence Data Source (www.lho.org.uk/
viewResource.aspx?id=9443) and contacted theWHOViolence
and Injury Programme to inquire about any screening studies
fitting our criteria. We also examined the reference lists of
included papers and performed forwards and backwards citation
tracking.
Data collection
Two reviewers (LO’D andAT) independently assessed abstracts.
If reviewers disagreed about abstract inclusion, this was resolved
by reading the full study followed by discussion. A third
reviewer (KH) was consulted to resolve any remaining
difference of opinion. A similar process was followed in
selecting studies from the full text articles retrieved. Two
reviewers (LO’D and AT) independently extracted data from
papers included in the review and entered them onto an
electronic data collection form. The primary outcomes
comprised:
• Identification of intimate partner violence (data based on
clinical encounter)
• Information giving and referrals to support agencies
(including take-up rates when available).
The secondary outcomes comprised:
• Intimate partner violence
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• Women’s physical and psychosocial health
• Occurrence of adverse outcomes
• Cost benefit.
Any missing information or clarification was requested from
corresponding authors. Data were entered into ReviewManager
(Revman) 5.1 software.16 Two reviewers (LO’D and AT)
assessed risk of bias using Revman’s risk of bias assessment
tool.17
Data analysis
For binary outcomes, we calculated a standard estimation of the
risk ratio with random effects and a 95% confidence interval
from studies that could be pooled.17 For outcomes for which
data from studies could not be pooled (because of lack of
comparable studies—for example, heterogeneous methods of
measurement or insufficient data being reported or available
from authors), we reported the results as reported in individual
studies. Missing data and dropout rates were assessed by
comparing numbers analysed with numbers enrolled and by
examining the variation in denominators. We used published
imputed figures for missing data (to report the results) when
available. Participants were analysed in the groups to which
they were randomised. We used random effects models to
manage study heterogeneity16 and performed subgroup analyses
for type of healthcare setting. We calculated absolute benefit
by calculating assumed benefit (unscreened) by summing the
number of identified or referred but unscreened women and
then calculated this for the rate per 1000. We then calculated
the corresponding benefit (screened) and confidence intervals
by multiplying the assumed benefit by the risk ratios and
confidence intervals of unscreened to screened women. Finally,
absolute benefit was calculated as 1000 ×ACR× (1−RR), where
ACR is the assumed control risk based on the number per 1000
and RR is the risk ratio.17 To test for heterogeneity, we included
the I2 statistic and 95% confidence interval to measure the
proportion of variation of the estimated treatment effect
attributable to heterogeneity across the studies, rather than to
sampling error. The I2 statistic was interpreted according to
Cochrane guidelines, with a result of 0-29% being low, 30-50%
moderate, and 50-90% considerable heterogeneity, with a
significance of P=0.05.17 We used the GRADE evaluation of
evidence to grade the review findings: high quality (further
research is unlikely to change our confidence in the estimate of
effect), moderate quality (further research is likely to have an
important impact on our confidence in the estimate of effect
and might change it), and low quality (further research is likely
to have an important impact on our confidence in the estimate
of effect and is likely to change it).18
Results
Searches generated 6513 unique abstracts (fig 1⇓). We included
11 studies in the review (see appendix for full details of study
characteristics); all were conducted in high income countries
and the 13 027 women recruited were sociodemographically
diverse. Women recruited in antenatal clinics tended to be
younger, while those in emergency clinics were older, but all
were in their reproductive years. Three studies were evaluated
as “high risk” on four of the seven criteria for risk of bias,19-21
with four studies scoring “low risk” on four criteria (table
1⇓).22-25 Dropout rates were low (see appendix), with the
exception of the study by MacMillan and colleagues26 (which
had substantially longer follow-up periods). Though they
reported imputed data, none of the data reported were
meta-analysed in our review. The only other study to report
imputed data was by Ahmad and colleagues25; we used their
imputed figures for detection in our (identification)
meta-analysis.
Identification by clinician
We pooled six studies in a meta-analysis of the effect of
screening on identification of intimate partner violence (fig 2⇓);
all but one20 consisted of a computer assisted self completion
screening process, with positive results conveyed to clinicians
(see appendix). Each study measured “identification” in such a
way that data were comparable (for instance, based on clinical
encounter). Screening increased identification by 133% (risk
ratio 2.33, 95% confidence interval 1.39 to 3.89) compared with
usual care. In most cases, the proportion of women identified
was small, ranging from 3%21 to 17%.25
Five studies were excluded from the meta-analysis of
identification of exposure to intimate partner violence.
Koziol-McLain and colleagues examined re-victimisation,23 and
MacMillan and colleagues selected intimate partner violence
and women’s quality of life as primary outcomes.26 For the latter
study, of all women with positive results on screening, we
estimated identification based on proportions of women who
discussed intimate partner violence with their clinicians in the
screened (44%, 88/199) versus non-screened (8%, 17/212)
groups. We could not, however, include this study in the main
analysis in which the denominator was all enrolled women.
Kataoka and colleagues reported only prevalence rates in written
(29%, 48/163) versus face to face (19%, 32/165) inquiry.22
Similarly, the 2006 study byMacMillan and colleagues reported
on prevalence (4.1-17.7% at 12 months) across emergency
departments, family practices, and women’s clinics.19 Klevens
and colleagues compared disclosure to clinicians (8.7%, 4/46)
with women’s disclosure via audio computer assisted self
interviews (A-CASI) (21.3%, 17/80).24 While this study did
report that three women (of 80) in the A-CASI group
subsequently discussed abuse with their clinician, identification
was not measured consistently across the groups and therefore
we excluded it.
Information giving, referrals, and take up of
services
Three studies were included in the meta-analysis of referrals
(fig 3⇓). These were referrals to social workers,21 an in house
advocacy programme and other off site services,24 and an on
site nurse counsellor.25 While the pooled effect (risk ratio 2.67,
95% confidence interval 0.99 to 7.20) was in favour of the
screening intervention increasing referrals to supportive services
in hospital or community, the absolute numbers of referrals
were low and the difference was not significant at the 5% level.
Data related to information giving, as well as the take up of
services, were too heterogeneous to allowmeta-analysis of either
outcome. For example, Rhodes and colleagues defined provision
of services for intimate partner violence as safety assessment,
counselling by the health provider/social worker, and/or
provision of information about resources.27 In that study, 7.6%
(21/262) of the screened urban women received services
comparedwith 3.6% (10/275) of the unscreenedwomen. Among
screened suburban women, 2.5% (4/159) received services
compared with none of the 171 unscreened women. Trautman
and colleagues found that 4.3% (18/411) of screened women
received social work assistance for intimate partner violence
compared with 1% (2/194) of women in the comparison group.21
In the study by Klevens and colleagues, 4/36 women (11%)
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who had face to face screening reported at one week that they
had taken up services from the computer printout of resources
compared with 2/66 women (3%) in the computer (comparison)
group.24 Koziol-McLain and colleagues found no differences
on resource use based on the community resource checklist28
after three months.23 Ahmad and colleagues reported that
clinicians discussed safety with nine of the 25 (36%) women
identified in the screened group and with only one of 12 (8%)
women identified in the comparison group.25 Follow-up
appointments were set up with 20/25 women in the screened
group compared with 8/12 of non-screened women.
Projected benefit of screening in terms of
identification and referral
From a base of 31.8/1000 abused women being identified in
usual care, a screening programme would add an additional 42
women (95% confidence interval 12 to 92). From 7.4/1000
referred in usual care, screening for intimate partner violence
would add an additional 12 referrals (7 to 50) (table 2⇓).
Subgroup analyses
In subgroup analyses (fig 4⇓), two studies tested screening in
antenatal settings.We estimated a greater than 300% likelihood
of increased identification by clinicians in screened pregnant
populations, although we are cautious about this inference as
the confidence intervals were wide. In the three studies that
evaluated identification from screening in emergency settings,
we estimated a 161% greater likelihood of clinicians identifying
women experiencing intimate partner violence.While the effect
size was larger in antenatal settings, the confidence intervals
overlapped for the effects in the two settings.
Intimate partner violence
Two studies measured subsequent exposure to intimate partner
violence among screened versus non-screened women. Both
studies used the composite abuse scale29 but had different
denominators and timelines. Koziol-McLain and colleagues
measured recurrent intimate partner violence after three months
among all women.23 MacMillan and colleagues measured
recurrent intimate partner violence after 6, 12, and 18 months
in women who screened positive at baseline.26 Both studies
found a non-significant reduction in such violence after
screening, with similar point estimates of effect: odds ratio 0.86
(95% confidence interval 0.39 to 1.92) in the study by
Koziol-McLain and colleagues at three months’ follow-up23 and
0.88 (0.43 to 1.82) at 18 months in the study by MacMillan and
colleagues.26
Women’s physical and psychosocial health
Only the study by MacMillan and colleagues26 measured
physical health (SF-12).30 At 6, 12, and 18 months, the effect
favoured those who received screening, with increases at each
time point, but at 18 months, this was no longer a significant
effect (mean difference 1.57, 95% confidence interval −0.59 to
3.73). This study was also the only one to measure psychosocial
health. Overall, there was no evidence of impact on quality of
life or post-traumatic stress disorder, depression, or alcohol and
drug problems.
Occurrence of adverse outcomes
Studies measured women’s preferences for screeningmethod,19
acceptability,23 25 comfort levels,22 positive and negative
reactions,24 and overall satisfaction.27 Negative reactions to
screening were reported as negligible in the trial by Klevens
and colleagues.24 Koziol-McLain and colleagues reported no
adverse effects.23 Rhodes and colleagues found that inquiries
about and disclosures of intimate partner violence were
associated with higher patient satisfaction with care.27Only one
study, however, measured potential harm, using a newmeasure
developed for the trial, the consequences of screening tool
(COST).26 The mean score of 3.52 (SD 3.24) on the eight item
effects on quality of life subscale supported the view that being
asked screening questions about intimate partner violence was




In this review of the 11 trials testing screening for intimate
partner violence versus routine care, we found moderate
evidence that screening in healthcare settings in high income
countries increases rates of identification of women subject to
this sort of violence compared with usual care. This was
particularly the case in the two studies set in antenatal settings;
in a hospital outpatient setting there was no significant increase
in identification. When there was an increase in identification,
it was modest compared with the prevalence of intimate partner
violence amongwomen attending healthcare settings.2We found
little evidence that screening increases referrals to support
services. Furthermore, though not meta-analysed, the trials did
not find an impact of screening on improved outcomes for
women. Only two studies measured the impact of screening on
re-exposure to intimate partner violence and did not find that
screening alone reduces abuse. Only one study measured
potential harm from screening.
Thus, weighing up the limited evidence of benefit beyond
identification and the fact that most studies do not measure the
risks of screening, the current evidence does not support
screening programmes for intimate partner violence in healthcare
settings. There remains an urgent need to conduct trials that will
be able to clearly evaluate the potential for such screening to
improve women’s health and social outcomes and its potential
to do harm.
Types and context of studies
Screening for intimate partner violence in healthcare settings is
a complex intervention, which makes the choice of inclusion
criteria for a systematic review problematic. Definitions of
screening for intimate partner violence are often vague or
absent.31We included only studies of interventions that involved
a consultation between patient and clinician; we excluded studies
of screening programmes that were followed by structured
interventions such as advocacy or therapeutic interventions.
Studies were conducted in urban and rural settings in
predominantly high income countries with legislation and
specialist support services for intimate partner violence to which
clinicians could refer.
They were situated in a range of healthcare settings. Screening
was most effective in the antenatal setting, possibly because
screening can offer multiple opportunities for women at a key
turning point in their lives. Emergency care settings are subject
to high staff turnover, limited ability to sustain training, and a
crisis atmosphere, so that the opportunity to help might be
limited, but again social work help might be available. Different
opportunities exist in primary care, depending on community
resources. While more women are identified in antenatal
settings, the lack of evidence for improved outcomes suggests
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targeted screening programmes require redesign and possibly
more resources (for example, system support and effective
sustainable health professional training) followed by trial
evaluation to see if there is long term benefit for women and
babies. Studies used various screening tools and either deployed
clinician screening or communication to the clinician of a
positive screening result derived from a self completion method
(computer or written survey), compared with usual care.
Identification, referral, and distribution of information about
intimate partner violence and resources were primary outcomes,
although were not used in inclusion criteria. Follow-up time
varied from immediately after the intervention for identification
rates and referral to 18 months for health outcomes, recurrence
of intimate partner violence, and resource use.We acknowledge
the fundamental importance of reduction in intimate partner
violence as an outcome of these trials. As women have limited
control over the violence they experience, however, process
outcomes (such as identification and referral) might be more
meaningful in studies with short follow-up periods as tends to
be the case in screening trials.
Strengths and limitations
Meta-analysis was limited by heterogeneity in outcomes and
approaches to measurement across included studies. In our
review, “identification” referred to any form of acknowledgment
by a clinician during a consultation that the woman had
experienced exposure to intimate partner violence. The clinical
interaction was seen as important in increasing the likelihood
that a woman with a positive result on screening would receive
an appropriate response. Identification might have been
underestimated by relying on clinicians’ willingness to document
intimate partner violence in women’s charts21-32 or participants’
recall of what occurred during encounters.20 33 Audio-recording
encounters to collect data on identification could also have
influenced clinicians and patients’ willingness to raise or discuss
the issue.25 27 Rates of identification by clinicians were low
relative to the rates of disclosure in the computerised or written
assessment. For example, Rhodes and colleagues found that of
the 83 participants in the intervention group who reported
intimate partner violence on the computer self assessment (that
was subsequently conveyed to the clinician), just 19 cases were
documented by clinicians in patients’ charts. In another study,
just 48% of encounters with a prompt for clinicians led to a
discussion of intimate partner violence.27 This reflects the
barriers that both women and clinicians experience in relation
to approaching the problem of intimate partner violence in
women’s lives.10 34 It was also difficult to use referral as an
outcome for analysis, with some studies defining it as the
provision of lists of resources/services and others alluding to
more formal processes of immediate referral to social work and
other clinical/support services. Thus, future trials need to be
attuned to the methodological challenge of operationalising
outcomes in this context,35 including not treating the provision
of a list of services as “a referral.” One of the criticisms
commonly raised against the implementation of screening is
that there has been insufficient study of whether screening for
intimate partner violence in healthcare settings can be harmful
to women.36 The one trial that systematically assessed harmwas
reassuring on that count.26 A recent trial that added a brief
counselling intervention after screening and used the same harm
measure also reported no adverse effect of screening.37
Monitoring harm with specific validated measures is an
imperative for future studies dealing with intimate partner
violence in healthcare settings. None of the trials included an
economic analysis. Both the proportions of women choosing
not to disclose and the impact of false identification on women’s
lives need further investigation before we can fully understand
the effectiveness of screening.
Only four studies were assessed as being at low risk of bias for
four of the seven domains examined. While nine studies
minimised the risk of selection bias through effective random
sequence allocation, lack of blinding of participants and
providers (performance bias), and the associated potential for
differential behaviours across study groups, was the most
consistent threat to validity generally. This was unsurprising
given that it is difficult if not impossible to blind providers in
studies of complex interventions. This is particularly true in a
cluster randomised design such as a study that sought to
determine if clinicians using a particular assessment form
detected more antenatal psychosocial concerns in pregnant
women compared with clinicians providing usual prenatal care.20
Despite the difficulties in minimising performance bias, cluster
trials do protect against contamination associated with crossover
effects. Another limitation arises from the complex ethical
challenges of conducting true randomised experiments of
services for those experiencing intimate partner violence: most
studies involved offering some relevant information to
participants in the comparison arm. Thus, future trials need to
weigh up the costs and benefits of minimising the risk of bias
because, while reducing bias will optimise the validity of study
findings, it must also be feasible and ethical. Studies in intimate
partner violence can be particularly susceptible to contextual
factors because of the sensitive and stigmatised nature of such
violence. This underscores the need for qualitative and process
modelling methods to investigate external factors impacting on
outcomes.38 39 Few studies reported a process evaluation, and
the published reports often lacked detail about organisational
context and how clinicians were trained and supported to
undertake screening.
Implications for clinicians and policymakers
Although some governments and healthcare policy and
professional associations mandate screening for intimate partner
violence,9 40 that position is not consistent with previous
systematic reviews5-41 and conflicts with the recent guidance
from the UK National Institute for Health and Care Excellence
(NICE)42 and WHO.43 Neither this systematic review nor the
totality of evidence from other reviews support the
implementation of routine screening for intimate partner
violence at this time. Although identification of affected women
patients increases, the absolute number of women identified is
modest in comparison with the numbers of women screened
and the likely prevalence of intimate partner violence, so a
screening programme might provide false reassurance to
healthcare providers and policymakers. Moreover, from the
small number of screening trials that measured health outcomes
for women, there is insufficient evidence of benefit derived to
the women screened.
Unanswered questions and future research
Future trials should be conducted to provide evidence for
whether violence decreases and whether women’s wellbeing
increases. To do this, trials must be carried out in a setting with
adequate resources to support the women identified. It is
essential that future research recognises the complexity of trial
design, implementation, and evaluation. There is a need for well
defined theoretically informed interventions, a rationale for
outcome selection andmeasurement, and investigation of context
and process. Finding innovative approaches to minimising
performance bias as well as increased description (in process
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evaluation and published protocols) could strengthen the
evidence coming from future studies. Cluster randomisation
without recruitment of individual participants is one ethical
method for designing trials of interventions for intimate partner
violence, with patients unaware that they are in a trial.44 More
studies are needed that examine different methods of
identification of affected women, including a range of healthcare
settings and diverse populations. We must examine the social
and economic benefits for the differing strategies of screening
versus case finding. The question of whether to move towards
targeting screening to subgroups of high risk women also
remains unanswered. A criticism of screening trials generally
is insufficient intervention after disclosure. More research is
necessary to evaluate the effectiveness of screening linked with
advocacy,45 social support,46 and structured clinician support37
and other therapeutic interventions. Generally, we need to shift
research effort towards testing the effectiveness of interventions
for women who disclose abuse, whatever the method of
identification.47
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Tables
Table 1| Risk of bias summary: review authors’ judgments about each risk of bias item for each included study of screening women for
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Moderate3564 (6)2.33 (1.39 to 3.89)42 (12 to 92)74 (44 to 124)32Identification
Low1400 (3)2.67 (0.99 to 7.20)12 (0 to 43)19 (7 to 50)7Referral
*Assumed benefit was from sum of identified or referred but unscreened women and calculated for rate per 1000. Corresponding benefit and confidence intervals
calculated by multiplying assumed benefit by risk ratio (RR) and CIs of unscreened to screened women.
†Absolute benefit calculated with formula 1000 × ACR × (1−RR) where ACR is assumed control risk and based on number per 1000.17
‡Risk ratio.
§GRADE Working Group grades of evidence.18
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Figures
Fig 1 Flow diagram for selection of studies of screening for intimate partner violence in healthcare settings
Fig 2 Effect of screening v usual care on identification of intimate partner violence in healthcare settings
Fig 3 Effect of screening versus comparison on referrals for intimate partner violence in healthcare settings
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Fig 4 Effect of screening on identification of women experiencing intimate partner violence by location subgroup
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